Els Everaert
Overview
Explore the profile of Els Everaert including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
124
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fontaine C, Libert I, Echterbille M, Bonhomme V, Botterman J, Bourgonjon B, et al.
Support Care Cancer
. 2024 Nov;
32(12):811.
PMID: 39567437
Background: Pain is reported in 66% of cancer patients with advanced disease. Adequate pain management is a cornerstone of comprehensive supportive cancer care. Purpose: The purpose of this study was...
2.
De Laere B, Crippa A, Discacciati A, Larsson B, Persson M, Johansson S, et al.
Nat Med
. 2024 Aug;
30(11):3381.
PMID: 39198712
No abstract available.
3.
De Laere B, Crippa A, Discacciati A, Larsson B, Persson M, Johansson S, et al.
Nat Med
. 2024 Aug;
30(11):3291-3302.
PMID: 39164518
ProBio is the first outcome-adaptive platform trial in prostate cancer utilizing a Bayesian framework to evaluate efficacy within predefined biomarker signatures across systemic treatments. Prospective circulating tumor DNA and germline...
4.
Boegemann M, Khaksar S, Bera G, Birtle A, Dopchie C, Dourthe L, et al.
BMC Cancer
. 2019 Jan;
19(1):60.
PMID: 30642291
Background: With the recent introduction of novel treatment options, real-world data from patients with metastatic castration-resistant prostate cancer (mCRPC) are required to better understand the impact on routine clinical practice....
5.
Mayrhofer M, De Laere B, Whitington T, Van Oyen P, Ghysel C, Ampe J, et al.
Genome Med
. 2018 Nov;
10(1):85.
PMID: 30458854
Background: There are multiple existing and emerging therapeutic avenues for metastatic prostate cancer, with a common denominator, which is the need for predictive biomarkers. Circulating tumor DNA (ctDNA) has the...
6.
De Laere B, Oeyen S, Van Oyen P, Ghysel C, Ampe J, Ost P, et al.
Prostate
. 2018 Feb;
78(6):435-445.
PMID: 29431193
Background: The outcome to treatment administered to patients with metastatic castration-resistant prostate cancer (mCRPC) greatly differs between individuals, underlining the need for biomarkers guiding treatment decision making. Objective: To investigate...
7.
Van Praet C, Rottey S, Van Hende F, Pelgrims G, Demey W, Van Aelst F, et al.
Clin Genitourin Cancer
. 2017 Mar;
15(4):502-508.
PMID: 28258960
Background: Abiraterone acetate (AA) increases overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel. However, survival time varies substantially between individuals. Our goal was...
8.
Van Praet C, Rottey S, Van Hende F, Pelgrims G, Demey W, Van Aelst F, et al.
Urol Oncol
. 2016 Feb;
34(6):254.e7-254.e13.
PMID: 26850781
Background: Abiraterone acetate (AA) is licensed for treating metastatic castration-resistant prostate cancer (mCRPC). Real-world data on oncological outcome after AA are scarce. The current study assesses efficacy and safety of...
9.
Amant F, Coosemans A, Renard V, Everaert E, Vergote I
Int J Gynecol Cancer
. 2009 Apr;
19(2):245-8.
PMID: 19396002
The clinical impact of ET-743 (trabectedin; Yondelis) in women with leiomyosarcoma and undifferentiated uterine sarcoma in patients previously treated with chemotherapy is investigated. Current data show a clinical benefit in...
10.
Everaert E, Neyns B, Joosens E, Strauven T, Branle F, Menten J
J Neurooncol
. 2004 Nov;
70(1):37-48.
PMID: 15527106
Temozolomide (TMZ) has demonstrated activity and acceptable toxicity for the treatment of recurrent high-grade gliomas in prospective phase II studies. Limited information is available on TMZ when prescribed outside a...